Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

An economic evaluation attached to a single-centre, parallel group, unmasked, randomized controlled trial of a 3-day intensive social cognitive treatment (can do treatment) in patients with relapsing remitting multiple sclerosis and low disability.

van Mastrigt GA, Evers SM, Heerings M, Visser LH, Ruimschotel RP, Hussaarts A, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Bos M, van Droffelaar M, Jongen PJ.

J Med Econ. 2019 May 14:1-14. doi: 10.1080/13696998.2019.1609300. [Epub ahead of print]

PMID:
31084442
2.

Caregiver strain among life partners of persons with mild disability due to relapsing-remitting multiple sclerosis.

van der Hiele K, van Gorp DAM, Heerings MAP, Jongen PJ, van der Klink JJL, Beenakker EAC, van Eijk JJJ, Frequin STFM, van Geel BM, Hengstman GJD, Hoitsma E, Mostert JP, Verhagen WIM, de Gans K, Zemel D, Middelkoop HAM, Visser LH.

Mult Scler Relat Disord. 2019 Jun;31:5-11. doi: 10.1016/j.msard.2019.03.005. Epub 2019 Mar 6.

3.

Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey.

Giordano A, Liethmann K, Köpke S, Poettgen J, Rahn AC, Drulovic J, Beckmann Y, Sastre-Garriga J, Galea I, Heerings M, Jongen PJ, Vettorazzi E, Solari A, Heesen C; AutoMS group.

PLoS One. 2018 Nov 29;13(11):e0208004. doi: 10.1371/journal.pone.0208004. eCollection 2018.

4.

The capability set for work - correlates of sustainable employability in workers with multiple sclerosis.

van Gorp DAM, van der Klink JJL, Abma FI, Jongen PJ, van Lieshout I, Arnoldus EPJ, Beenakker EAC, Bos HM, van Eijk JJJ, Fermont J, Frequin STFM, de Gans K, Hengstman GJD, Hupperts RMM, Mostert JP, Pop PHM, Verhagen WIM, Zemel D, Heerings MAP, Reneman MF, Middelkoop HAM, Visser LH, van der Hiele K.

Health Qual Life Outcomes. 2018 Jun 1;16(1):113. doi: 10.1186/s12955-018-0942-7.

5.

[Clinical drug profiles: an instrument to improve shared decision-making].

Jongen PJ.

Ned Tijdschr Geneeskd. 2018;162:D2162. Dutch.

PMID:
29623864
6.

Improved health-related quality of life, participation, and autonomy in patients with treatment-resistant chronic pain after an intensive social cognitive intervention with the participation of support partners.

Jongen PJ, Ruimschotel RP, Museler-Kreijns YM, Dragstra T, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Lagrand R, Donders R, Hartog A.

J Pain Res. 2017 Dec 1;10:2725-2738. doi: 10.2147/JPR.S137609. eCollection 2017.

7.

Letter re: Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

Jongen PJ.

Neurology. 2017 Nov 7;89(19):2022. doi: 10.1212/WNL.0000000000004620. No abstract available.

PMID:
29109135
8.

Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling.

Kremer IEH, Evers SMAA, Jongen PJ, Hiligsmann M.

Health Expect. 2018 Feb;21(1):171-180. doi: 10.1111/hex.12599. Epub 2017 Jul 21.

9.

Adherence to Web-Based Self-Assessments in Long-Term Direct-to-Patient Research: Two-Year Study of Multiple Sclerosis Patients.

Jongen PJ, Kremer IEH, Hristodorova E, Evers SMAA, Kool A, van Noort EM, Hiligsmann M.

J Med Internet Res. 2017 Jul 21;19(7):e249. doi: 10.2196/jmir.6729.

10.

Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

Jongen PJ.

CNS Drugs. 2017 Jul;31(7):603. doi: 10.1007/s40263-017-0457-5. No abstract available.

PMID:
28688015
11.

Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

Jongen PJ.

CNS Drugs. 2017 Jul;31(7):585-602. doi: 10.1007/s40263-017-0444-x. Review. Erratum in: CNS Drugs. 2017 Jul;31(7):603.

12.

Coping strategies in relation to negative work events and accommodations in employed multiple sclerosis patients.

van der Hiele K, van Gorp D, Benedict R, Jongen PJ, Arnoldus E, Beenakker E, Bos HM, van Eijk J, Fermont J, Frequin S, van Geel BM, Hengstman G, Hoitsma E, Hupperts R, Mostert JP, Pop P, Verhagen W, Zemel D, Frndak SE, Heerings M, Middelkoop H, Visser LH.

Mult Scler J Exp Transl Clin. 2016 Nov 24;2:2055217316680638. doi: 10.1177/2055217316680638. eCollection 2016 Jan-Dec.

13.

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis.

Traboulsee AL, Cornelisseª P, Sandberg-Wollheim M, Uitdehaag BM, Kappos L, Jongen PJ, Constantinescu CS, di Cantogno EV, Li DK.

Mult Scler J Exp Transl Clin. 2016 Sep 6;2:2055217316666406. doi: 10.1177/2055217316666406. eCollection 2016 Jan-Dec.

14.
15.

Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.

Kremer IE, Evers SM, Jongen PJ, van der Weijden T, van de Kolk I, Hiligsmann M.

PLoS One. 2016 Nov 3;11(11):e0164862. doi: 10.1371/journal.pone.0164862. eCollection 2016.

16.

Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later.

Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Duyverman L, van der Zande A, Valkenburg-Vissers J, van Droffelaar M, Lemmens W, Donders R, Visser LH.

BMC Res Notes. 2016 Jul 29;9:375. doi: 10.1186/s13104-016-2173-5.

17.

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines.

Jongen PJ, Lemmens WA, Hupperts R, Hoogervorst ELj, Schrijver HM, Slettenaar A, de Schryver EL, Boringa J, van Noort E, Donders R.

Patient Prefer Adherence. 2016 May 24;10:909-17. doi: 10.2147/PPA.S108121. eCollection 2016.

18.

Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.

Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P.

J Neurol. 2016 Aug;263(8):1641-51. doi: 10.1007/s00415-016-8183-3. Epub 2016 Jun 7.

19.

An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol.

Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Evers S, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Bos M, van Droffelaar M, Lemmens WA, Donders R, van der Zande A, Visser LH.

BMC Neurol. 2016 May 28;16:81. doi: 10.1186/s12883-016-0593-4.

20.

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.

Visser LH, Heerings MA, Jongen PJ, van der Hiele K.

Patient Prefer Adherence. 2016 Apr 26;10:659-67. doi: 10.2147/PPA.S106155. eCollection 2016.

21.

The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: utilization and valuation by patients.

Jongen PJ, Sinnige LG, van Geel BM, Verheul F, Verhagen WI, van der Kruijk RA, Haverkamp R, Schrijver HM, Baart JC, Visser LH, Arnoldus EP, Gilhuis HJ, Pop P, Booy M, Heerings M, Kool A, van Noort E.

Patient Prefer Adherence. 2016 Mar 3;10:243-50. doi: 10.2147/PPA.S93786. eCollection 2016.

22.

Risk indicator taxonomy for supervision of clinical trials on medicinal products.

Jongen PM, van den Bogert CA, van de Laar CW, Notenboom K, Hille ET, Hegger I.

Curr Med Res Opin. 2016 Jul;32(7):1269-76. doi: 10.1185/03007995.2016.1170671. Epub 2016 Apr 21.

PMID:
27009363
23.

The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results.

Jongen PJ, Sinnige LG, van Geel BM, Verheul F, Verhagen WI, van der Kruijk RA, Haverkamp R, Schrijver HM, Baart JC, Visser LH, Arnoldus EP, Gilhuis HJ, Pop P, Booy M, Lemmens W, Donders R, Kool A, van Noort E.

Patient Prefer Adherence. 2015 Dec 11;9:1741-50. doi: 10.2147/PPA.S93783. eCollection 2015.

24.

Preferences of Patients With Multiple Sclerosis for Attributes of Disease Modifying Drugs In Decision-Making: A Nominal Group Technique And Best-Worst Scaling.

Kremer IE, Evers SM, Jongen PJ, Dowie J, van der Weijden T, van de Kolk I, Hiligsmann M.

Value Health. 2015 Nov;18(7):A761. doi: 10.1016/j.jval.2015.09.2487. Epub 2015 Oct 20. No abstract available.

25.

Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based study.

Jongen PJ, Blok BF, Heesakkers JP, Heerings M, Lemmens WA, Donders R.

Health Qual Life Outcomes. 2015 Oct 30;13:175. doi: 10.1186/s12955-015-0368-4.

26.
27.

The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting Multiple Sclerosis.

van der Hiele K, van Gorp DA, Heerings MA, van Lieshout I, Jongen PJ, Reneman MF, van der Klink JJ, Vosman F, Middelkoop HA, Visser LH; MS@Work Study Group.

BMC Neurol. 2015 Aug 12;15:134. doi: 10.1186/s12883-015-0375-4.

28.
29.

Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis?

Jongen PJ, Wesnes K, van Geel B, Pop P, Schrijver H, Visser LH, Gilhuis HJ, Sinnige LG, Brands AM.

Mult Scler Int. 2015;2015:960282. doi: 10.1155/2015/960282. Epub 2015 Apr 29.

30.

Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis.

de Bock L, Somers K, Fraussen J, Hendriks JJ, van Horssen J, Rouwette M, Hellings N, Villar LM, Alvarez-Cermeño JC, Espiño M, Hupperts R, Jongen P, Damoiseaux J, Verbeek MM, De Deyn PP, D'hooghe M, Van Wijmeersch B, Stinissen P, Somers V.

J Immunol. 2014 Sep 1;193(5):2147-56. doi: 10.4049/jimmunol.1401166. Epub 2014 Aug 1.

31.

Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.

Jongen PJ, Lehnick D, Koeman J, Frequin S, Heersema D, Kornips B, Schyns-Soeterboek A, Visser LH, Schiphof P, Valkenburg A, Hiel J; FOCUS Extension Study Group.

J Neurol. 2014 Aug;261(8):1469-76. doi: 10.1007/s00415-014-7363-2. Epub 2014 May 3.

32.

Relationship between working hours and power of attention, memory, fatigue, depression and self-efficacy one year after diagnosis of clinically isolated syndrome and relapsing remitting multiple sclerosis.

Jongen PJ, Wesnes K, van Geel B, Pop P, Sanders E, Schrijver H, Visser LH, Gilhuis HJ, Sinnige LG, Brands AM; COGNISEC Study Group.

PLoS One. 2014 May 1;9(5):e96444. doi: 10.1371/journal.pone.0096444. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105654.

33.

Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.

Jongen PJ, Ruimschotel R, Heerings M, Hussaarts A, Duyverman L, van der Zande A, Valkenburg-Vissers J, Wolper H, van Droffelaar M, Lemmens W, Donders R, Visser LH.

Health Qual Life Outcomes. 2014 Mar 19;12:40. doi: 10.1186/1477-7525-12-40.

34.

Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis.

Rouwette M, Noben JP, Van Horssen J, Van Wijmeersch B, Hupperts R, Jongen PJ, Verbeek MM, De Deyn PP, Stinissen P, Somers V.

J Neurochem. 2013 Aug;126(4):483-92. doi: 10.1111/jnc.12335. Epub 2013 Jul 1.

35.

Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment.

Jongen PJ, Sanders E, Zwanikken C, Koeman J, Visser LH, Koopmans P, Lehnick D; OPTIVIT study group.

Patient Prefer Adherence. 2013 Apr 9;7:293-300. doi: 10.2147/PPA.S40173. Print 2013.

36.

Cognitive impairment in multiple sclerosis.

Jongen PJ, Ter Horst AT, Brands AM.

Minerva Med. 2012 Apr;103(2):73-96. Review.

PMID:
22513513
37.

Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.

Jongen PJ, Sindic C, Sanders E, Hawkins S, Linssen W, van Munster E, Frequin S, Borm G; Functional Composite and Quality of Life in Avonex-treated Relapsing Multiple Sclerosis Patients Study Group.

PLoS One. 2011;6(10):e26568. doi: 10.1371/journal.pone.0026568. Epub 2011 Oct 25.

38.

Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.

Edgar C, Jongen PJ, Sanders E, Sindic C, Goffette S, Dupuis M, Jacquerye P, Guillaume D, Reznik R, Wesnes K.

BMC Neurol. 2011 Jun 7;11:68. doi: 10.1186/1471-2377-11-68.

39.

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.

BMC Neurol. 2011 Mar 30;11:40. doi: 10.1186/1471-2377-11-40.

40.

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.

Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J; FOCUS study group.

Health Qual Life Outcomes. 2010 Nov 15;8:133. doi: 10.1186/1477-7525-8-133.

41.

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.

Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Epub 2010 Jun 9. Erratum in: Lancet Neurol. 2010 Aug;9(8):759.

PMID:
20542736
42.

Chitotriosidase activity in controls and multiple sclerosis.

Verbeek MM, Lefeber DJ, Jongen PJ.

Acta Neurol Scand. 2010 May;121(5):356-7. doi: 10.1111/j.1600-0404.2010.01339.x. Epub 2010 Mar 1. No abstract available.

PMID:
20199517
43.

Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture.

Tjon Eng Soe SH, Kopsky DJ, Jongen PJ, de Vet HC, Oei-Tan CL.

Mult Scler. 2009 Nov;15(11):1376-7. doi: 10.1177/1352458509107020. No abstract available.

PMID:
19965561
44.

Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.

Verbeek MM, Notting EA, Faas B, Claessens-Linskens R, Jongen PJ.

Acta Neurol Scand. 2010 May;121(5):309-14. doi: 10.1111/j.1600-0404.2009.01242.x. Epub 2009 Nov 19.

PMID:
19925532
45.

Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.

Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G; Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients study group.

J Neurol. 2010 Apr;257(4):584-9. doi: 10.1007/s00415-009-5378-x. Epub 2009 Nov 18.

PMID:
19921303
46.

Association between MRI parameters and the MS severity scale: a 12 year follow-up study.

Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F.

Mult Scler. 2009 May;15(5):632-7. doi: 10.1177/1352458509102617.

PMID:
19389751
47.

Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.

Somsen GW, Tak YH, Toraño JS, Jongen PM, de Jong GJ.

J Chromatogr A. 2009 May 1;1216(18):4107-12. doi: 10.1016/j.chroma.2009.02.063. Epub 2009 Feb 26.

PMID:
19272607
48.

Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis.

Jongen PJ, Lycklama a Nijeholt G, Lamers KJ, Doesburg WH, Barkhof F, Lemmens WA, Klasen IS, Hommes OR.

Eur Neurol. 2007;58(2):90-5. Epub 2007 Jun 12.

PMID:
17570915
49.

Neuromyelitis optica with clinical and histopathological involvement of the brain.

Hengstman GJ, Wesseling P, Frenken CW, Jongen PJ.

Mult Scler. 2007 Jun;13(5):679-82. Epub 2007 Feb 9.

PMID:
17548452
50.

Costs and quality of life in multiple sclerosis in The Netherlands.

Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, Polman C, Uitdehaag B.

Eur J Health Econ. 2006 Sep;7 Suppl 2:S55-64. Erratum in: Eur J Health Econ. 2007 Dec;8(4):359. Anten, Bert [added]; Ekman, Mattias [added]; Jongen, Peter J H [added]; Polman, Chris [added]; Uitdehaag, Bernard [added].

PMID:
17310343

Supplemental Content

Loading ...
Support Center